Sarah L. Draper

This paper designs an mRNA vaccine with fused SARS-CoV-2 RBDs from different variants to elicit cross-reactive antibodies without extensive somatic hypermutation.

This study shows that circRNA vaccine performance depends on RNA quality and epitranscriptomic modifications rather than innate immune activation.

This study optimizes an mRNA vaccine to enhance liver Trm cell induction by reducing type I interferon responses through improved manufacturing.

The paper identifies temporal expression patterns of liver-stage malaria antigens and shows that combining antigens with different temporal profiles improves vaccine efficacy.